ClinicalTrials.gg
TerminatedNCT04480138Updated Jul 12, 2022

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

A Phase 2 interventional study of Pegylated Interferon-α2b and Standard of Care in Covid19, sponsored by Zydus Lifesciences Limited. Terminated at 2 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Zydus Lifesciences Limited · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Due to non availability of eligible subjects and slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in COVID-19 with a site in Mexico — 12 open to participants now, 14 under way, 6 of them phase 3. COVID-19 · Mexico.

Enrollment
144th of 151
7 · median 200
Started
2020
with 118 others
Phase 2
28 of 198
1 open now
Registered
56th of 198
by date

Among the 198 studies in COVID-19 with a site in Mexico, this one is the 144th largest by enrollment of the 151 interventional ones that give a count, is one of 119 that started in 2020, is one of 28 in phase 2, and was the 56th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

12 of the 198 studies in COVID-19 with a site in Mexico are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in COVID-19 with a site in Mexico, or all of them as a file.
02

Study summary

This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.

Read the detailed description

This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Moderate COVID-19 subjects will be randomly assigned to receive test arm or reference arm in a 1:1 ratio.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to comprehend and willingness to sign a written ICF for the study.
  2. Male or non-pregnant females, ≥18 years of age at the time of enrolment.
  3. Understands and agrees to comply with planned study procedures.
  4. Agrees to the collection of pharyngeal swabs and blood sample as per protocol.
  5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen within one week
  6. Patients with SpO2 > 93% and respiratory rate \<30 breaths/min.
  7. Illness of any duration, and at least one of the following:

    1. Radiographic infiltrates by imaging (chest x-ray)
    2. Clinical assessment (evidence of rales/crackles or other clinical symptoms on exam).
  8. Women of must agree to use at least one primary form of

Exclusion criteria

Exclusion Criteria:

  1. /AST >5 times the .
  2. Patients with respiratory rate \<20 breaths/min and normal SpO2 with confirmed SARS-CoV-2 infection as determined by PCR (Mild COVID-19 subjects).
  3. Patients with respiratory rate ≥30 breaths/min and SpO2 at rest ≤93% (Severe COVID-19 subjects).
  4. Stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. \<30 mL/min/1.73 m2).
  5. Pregnant or breast feeding.
  6. Allergy to any study medication or usage of test drug during last 14 days prior to screening
  7. Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic disease which affect the vital organs severity, patients etc.) as per investigator's assessment.
  8. Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.
  9. Prolong (>450 ms).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Pegylated Interferon-α2b + Standard of care

    Test :- Pegylated Interferon-α2b + Standard of care (SOC) Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial.

    Drug: Pegylated Interferon-α2b · Other: Standard of Care

  • Active comparator
    Standard of Care

    Control: Standard of care Standard of care treatment will be provided as per regulatory recommendation and approval.

    Other: Standard of Care

Interventions

  • DrugPegylated Interferon-α2b

    1 mcg/kg on day 1 and day 8 after safety evaluations.

  • OtherStandard of Care

    Standard of care as per local authority

06

What researchers measure

Primary outcomes

  1. Change in Clinical status of subject on a 7-point ordinal scale

    1. Not hospitalized, no limitations on activities. 2. Not hospitalized, limitation on activities. 3. Hospitalized, not requiring supplemental oxygen. 4. Hospitalized, requiring supplemental oxygen. 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices. 6. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). 7. Death.

    Time frame: Week 2

Secondary outcomes

  1. PCR test

    PCR for SARS-CoV-2 in pharyngeal swab

    Time frame: Week 2 and Week 4

  2. Supplemental Oxygen

    Occurrence of supplemental Oxygen

    Time frame: Week 2 and Week 4

  3. Mechanical Ventilation

    Occurrence of Mechanical Ventilation

    Time frame: Week 2 and Week 4

  4. Incidence of Treatment-Emergent Adverse Events

    Occurence of Adverse events

    Time frame: Week 2 and Week 4

  5. C-reactive protein (CRP)

    Inflammatory Biomarker

    Time frame: Week 2 and Week 4

  6. Interleukin 6 (IL-6)

    Inflammatory Biomarker

    Time frame: Week 2 and Week 4

  7. D-dimer

    Inflammatory Biomarker

    Time frame: Week 2 and Week 4

  8. Interferon gamma

    type II class of interferons

    Time frame: Week 2 and Week 4

  9. Ferritin

    proteins

    Time frame: Week 2 and Week 4

  10. TNF alpha

    Inflammatory Biomarker

    Time frame: Week 2 and Week 4

  11. Interleukin 1-β

    Inflammatory Biomarker

    Time frame: Week 2 and Week 4

07

Study locations

2 sites
  • Avant Sante site 2
    Zapopan, Jalisco, Mexico
  • Avant Sante Site 1
    Monterrey, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2021, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 21, 2020
StartActual
Aug 11, 2020
Primary completionActual
Jun 21, 2021
CompletionActual
Jun 21, 2021
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04480138
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Aug 11, 2020
Primary completion
Jun 21, 2021
Completion
Jun 21, 2021
Last update
Jul 12, 2022

Study contacts

Dr Deven Parmar, MD
study director · Cadila Healthcare Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion